Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Share Café September 2021
21 slides from Neuroscientific Biopharmaceuticals's conference presentation, Sep 3, 2021
Slide 1: Novel Drug Therapies for Neurodegenerative Conditions
NOVEL DRUG THERAPIES FOR For personal use only NEURODEGENERATIVE CONDITIONS Company Presentation Share Café September 2021
Slide 2: Disclaimer
DISCLAIMER The purpose of the presentation is to provide an update of the business of For personal use only NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex
Slide 3: Leadership Team
LEADERSHIP TEAM For personal use only Abby Macnish, CFA Paul Rennie, MBM, MSTC Matt Liddelow, Mpharm Dr Anton Uvarov, PhD, Stephen Quantrill, NON-EXECUTIVE CHAIRMAN MD + CEO MBA MBA Company Secretary & CFO EXECUTIVE DIRECTOR + CSO NON-EXECUTIVE DIRECTOR Experienced biotechnology 14+ years experience
Slide 4: NeuroScientific Biopharmaceuticals Ltd
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) is developing peptide-based compounds that prevent neurodegeneration and stimulate neuro-regeneration NEUROLOGY Alzheimer’s disease, Multiple sclerosis, TARGETED PEPTIDES spinal cord injury
Slide 5: EmtinB: LRP-1 agonist that promotes neuronal survival & regeneration
EMTINB™: LRP-1 AGONIST THAT PROMOTES NEURONAL SURVIVAL & REGENERATION For personal use only METALLOTHIONEIN-IIA EMTINB LRP-1 TARGET INTRACELLULAR SIGNALLING P OH ERK K P K K Akt P CREB Expressed post damage in different Modelled on β-domain of Expressed by neurons, Activation of LRP1 stimulates tiss
Slide 6: EmtinB – Pipeline in a Product
EMTINB™ – PIPELINE IN A PRODUCT For personal use only INDICATION RESEARCH IND-ENABLING PHASE I PHASE 2 Alzheimer’s disease NEUROLOGY Multiple sclerosis Glaucoma OPHTHALMOLOGY Optic nerve atrophy EXPLORATORY Multiple Currently investigating Emtin peptides in preventing pulmonary fibrosis in indicatio
Slide 7: EmtinB Development Plan
EMTINB™ DEVELOPMENT PLAN For personal use only 2021 2022 Completion of Ph1 FIH neurology neurology IND- study enabling studies Q4 2021 Ph2 Alzheimer’s study Q4 2021 Q4 2022 Complete ocular IND-enabling Ph1 glaucoma study Ph2 glaucoma study studies Q1 2022 Q4 2022 Q4 2021 Please note: 7 Indicative ti
Slide 8: Neurology
For personal use only NEUROLOGY
Slide 9: Neurodegenerative Conditions Significantly Contribute to Global Burden of Disease
NEURODEGENERATIVE CONDITIONS SIGNIFICANTLY CONTRIBUTE TO GLOBAL BURDEN OF DISEASE For personal use only DEMENTIA & ALZHEIMER’S MULTIPLE SCLEROSIS DISEASE 50M people globally have dementia 2.5M global prevalence 70% dementias Alzheimer’s disease 20-50y age range of diagnosis Global prevalence driven
Slide 10: EmtinB Promotes Neuronal Survival & Regeneration
EMTINB™ PROMOTES NEURONAL SURVIVAL & REGENERATION Increases in vitro survival and regeneration of damaged neurons from different regions of CNS CORTEX HIPPOCAMPUS For personal use only ALZHEIMER’S MODEL SPINAL CORD: INJURY MODEL 10 11
Slide 11: EmtinB Promotes Remyelination in Multiple Sclerosis Model
EMTINB™ PROMOTES REMYELINATION IN MULTIPLE SCLEROSIS MODEL For personal use only Effect of EmtinB: % Increase in oligodendrocytes MULTIPLE SCLEROSIS MODEL Mature OGCs 875% OPCs 607% Increased the number of OPCs (A2B5+) by ~7x (+607% vs control p<0.001) and mature Control 100% oligodendrocytes (MAG
Slide 12: EmtinB Slowed Cognitive Decline in Alzheimers Model
EMTINB™ SLOWED COGNITIVE DECLINE IN ALZHEIMERS MODEL Significantly slowed progression of AD in gold standard mouse model (APPswe/PS1) For personal use only AD MOUSE MODEL EFFECT ON ASTROGLIOSIS Cognition: treatment for 48 days EmtinB 70% +7 Control 38% +5 0% 50% 100% Slowed progression of Alzheime
Slide 13: Ophthalmology
For personal use only OPHTHALAMOLOGY
Slide 14: Over 5% of Global Population Suffer Vision Loss Due to Damaged Optic Nerve
>5% OF GLOBAL POPULATION SUFFER VISION LOSS DUE TO DAMAGED OPTIC NERVE For personal use only GLAUCOMA Vitreous humour OPTIC NEURITIS Optic nerve 76M global prevalence 10M global prevalence 2nd leading cause of blindness 50% MS patients affected Irreversible damage to the optic nerve Leads to partial
Slide 15: Regenerating the Optic Nerve
REGENERATING THE OPTIC NERVE For personal use only No Treatment transection RAT TRANSECTION MODEL EmtinB precursor compound (MT-II): Stimulated regeneration of fully severed optic nerve by up to 1000um Treatment (>250% vs non-treated) from 1 dose transection Axonal regeneration was evident well
Slide 16: EmtinB is Neuroprotective in Glaucoma
EMTINB™ IS NEUROPROTECTIVE IN GLAUCOMA Demonstrated neuroprotection in pig model of IOP glaucoma NFHp Non-treatment NFHp EmtinB For personal use only GLAUCOMA PIG MODEL Increased intraocular pressure pig model replicates severe human glaucoma pathology; positive results in this model indicate dise
Slide 17: EmtinB Ocular Tissue Penetration
EMTINB™ OCULAR TISSUE PENETRATION PK and tissue distribution in rabbits administered EmtinB via intravitreal delivery For personal use only Retina: EmtinB labelled with OG488 present in retinal tissue 6-hours 24-hours 6-days PK studies for EmtinB conducted up to 14-days detected therapeutic concentr
Slide 18: Financial Metrics & Milestones
For personal use only FINANCIAL METRICS & MILESTONES
Slide 19: Financial Metrics & Milestones
FINANCIAL METRICS & MILESTONES For personal use only FINANCIALS IPO on ASX July 2018 (ASX: NSB) ~$13.5M cash on hand Funded through to completion of current Phase I clinical program ASX code NSB McRae Investments and AlphaSwiss significant shareholders Shares on issue 143M Price (23/08/2021)
Slide 20: Summary Overview
SUMMARY OVERVIEW NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD (ASX: NSB) For personal use only Drug development company with an advanced preclinical lead candidate called EmtinB; funded through to completion of Phase I program EmtinB targets LRP-1 expressed on the outside of neurons and neuroglia; MOA
Slide 21: For More Information
FOR MORE INFORMATION: For personal use only Matt Liddelow CEO & Managing Director [email protected] www.neuroscientific.com
NeuroScientific Biopharmaceuticals — Share Café September 2021 on 6ix